Solid phase transition of CS-891 enantiotropes during grinding

International Journal of Pharmaceutics

Volumn 255, Issue 1-2, 2003, Pages 69-79

  Yada, Shuichi ^a,b   Ohya, Masaoki ^a   Ohuchi, Yuko ^a   Hamaura, Takeshi ^a   Wakiyama, Naoki ^a   Usui, Fusao ^a   Kusai, Akira ^a   Yamamoto, Keiji ^b  

^a DAIICHI SANKYO CO   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Amorphous; Crystallization; Enantiotropic form; Grinding; Transformation

Indexed keywords

CS 891; ENZYME INHIBITOR; HORMONE INHIBITOR; N [1 (4 METHOXYPHENYL) 1 METHYLETHYL] 3 OXO 4 AZA 5A ANDROST 1 ENE 17BETA CARBOXAMIDE; UNCLASSIFIED DRUG;

ARTICLE; BIOTRANSFORMATION; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG EFFECT; DRUG EFFICACY; EQUILIBRIUM CONSTANT; GRINDING; HIGH TEMPERATURE; LOW TEMPERATURE; PHASE TRANSITION; PRIORITY JOURNAL; SOLID; X RAY CRYSTALLOGRAPHY; X RAY POWDER DIFFRACTION;

EID: 0037436893     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(03)00084-X     Document Type: Article

References (18)

1. Altmomare A., Burla M.C., Camalli M., Cascarano M., Giacovazzo C., Guagliardi A., Polidori G. SIR92 a program for automatic solution of crystal structure by direct method. J. Appl. Cryst. 27:1994;435-435.
2. Bartolomei M., Bertocchi P., Ramusino M.C., Santucci N., Valvo L. Physico-chemical characterization of the modifications I and II of (R, S) propranolol hydrochloride: solubility and dissolution. J. Pharm. Biomed. Anal. 21:1999;299-309.
3. Burger A., Lettenbichler A. Polymorphism and preformulation of lifibrol. Eur. J. Pharm. Biopharm. 49:2000;65-72.
4. Dunitz J.D., Bernstein J. Disappearing polymorphs. Acc. Chem. Res. 28:1995;193-200.
5. Fan, H., 1991. Structure Analysis Programs With Intelligent Control. Rigaku Corporation, Tokyo, Japan.
6. Gilmore C.J. MITHRIL - an integrated direct methods computer program. J. Appl. Cryst. 17:1984;42-46.
7. Koda A., Ito S., Itai S., Yamamoto K. Characterization of chloramphenicol palmitate and absorption assessments of chloramphenicol palmitate polymorphs. J. Pharm. Sci. Technol., Jpn. 60:2000;43-52.
8. Miyake A., Kema H., Kawabata T., Yasuda T., Otsuka M., Matsuda Y. X-ray powder diffraction study on the grinding effect of the polymorphs of a novel and orally effective uricosuric agent: FR76505. Drug Dev. Ind. Pharm. 20:1994;2881-2897.
9. Mura P., Cirri M., Faucci M.T., Ginès-Dorado J.M., Bettinetti G.P. Investigation of effect of grinding and co-grinding on physicochemical properties of glisentide. J. Pharm. Biomed. Anal. 30:2002;227-237.
10. Otsuka M., Otsuka K., Kaneniwa N. Relation between polymorphic transformation pathway during grinding and the physicochemical properties of bulk powders for pharmaceutical preparations. Drug Dev. Ind. Pharm. 20:1994;1649-1660.
11. Raghavan K., Dwivedi A., Campbell G.C. Jr., Johnston E., Levorse D., McCauley J., Hussain M. A spectroscopic investigation of losartan polymorphs. Pharm. Res. 10:1993;900-904.
12. Sugimoto M., Okagaki T., Narisawa S., Koida Y., Nakajima K. Improvement of dissolution characteristics and bioavailability of poorly water-soluble drugs by novel cogrinding method using water-soluble polymer. Int. J. Pharm. 160:1998;11-19.
13. van Hoof P., Lammers R., v. Puijenbroek R., v.d Schans M., Carlier P., Kellenbach E. Polymorphism of the CNS active drug Org 13011: the application of high temperature analysis to detect new polymorphs. Int. J. Pharm. 238:2002;215-228.
14. Wang Y., Wenslow R.M., McCauley J.A., Crocker L.S. Polymorphic behavior of an NK1 receptor antagonist. Int. J. Pharm. 243:2002;147-159.
15. Wenslow, R.M., Baum, M.W., Ball, R.G., Mccauley, J.A., Varsoloa, R.J., 2000. A spectroscopic and crystallographic study of polymorphism in an aza-steroid. J. Pharm. Sci. 1271-1285.
16. Yamaguchi T., Nishimura M., Okamoto R., Takeuchi T., Yamamoto K. Physicochemical stability of glassy 16-membered macrolide compounds. Chem. Pharm. Bull. 41:1993;1812-1816.
17. Yoshihashi Y., Kitano H., Yonemochi E., Terada K. Quantitative correlation between initial dissolution rate and heat of fusion of drug substance. Int. J. Pharm. 204:2000;1-6.
18. Yoshioka M., Hancock B.C., Zografi G. Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. J. Pharm. Sci. 83:1994;1700-1705.